Table 1. Overall Screening and Diagnosis Rates per Year.
Year | Men with VHA encounter, No. | Incident metastatic prostate cancer cases, No. | Screening PSA, %a | Prostate biopsy rateb | Incident nonmetastatic prostate cancer cases with Gleason score of 8-10, % | Incidence rate, per 100 000 menb | ||
---|---|---|---|---|---|---|---|---|
Yes | None in prior 3 y | Nonmetastatic prostate cancer | Metastatic prostate cancer | |||||
2005 | 4 678 412 | 844 | 47.2 | 23.8 | 200.6 | 15.5 | 99.3 | 5.2 |
2006 | 4 713 876 | 845 | 48.7 | 22.8 | 196.2 | 16.6 | 98.3 | 5.2 |
2007 | 4 735 010 | 798 | 49.6 | 21.7 | 209.4 | 16.6 | 105.3 | 4.9 |
2008 | 4 759 413 | 786 | 50.8 | 21.0 | 196.0 | 16.7 | 99.6 | 4.6 |
2009 | 4 910 792 | 914 | 50.1 | 20.9 | 185.6 | 17.5 | 97.3 | 5.3 |
2010 | 4 989 335 | 890 | 48.2 | 21.3 | 175.7 | 18.3 | 92.5 | 5.0 |
2011 | 5 101 613 | 984 | 47.5 | 21.5 | 176.5 | 18.5 | 91.9 | 5.3 |
2012 | 5 175 058 | 1039 | 43.2 | 22.9 | 152.9 | 18.9 | 79.8 | 5.4 |
2013 | 5 207 538 | 1087 | 40.6 | 24.7 | 141.8 | 18.9 | 75.1 | 5.6 |
2014 | 5 269 477 | 1130 | 39.4 | 26.6 | 129.6 | 20.4 | 70.6 | 5.8 |
2015 | 5 280 469 | 1251 | 38.6 | 29.0 | 136.9 | 21.0 | 73.8 | 6.5 |
2016 | 5 290 551 | 1403 | 37.9 | 30.7 | 137.3 | 21.4 | 73.8 | 7.0 |
2017 | 5 312 173 | 1651 | 37.8 | 31.7 | 137.5 | 22.8 | 74.2 | 8.2 |
2018 | 5 340 725 | 1722 | 37.5 | 32.4 | 142.0 | 23.2 | 79.5 | 8.0 |
2019 | 5 371 701 | 1700 | 37.0 | 33.2 | 138.5 | 23.8 | 77.2 | 7.9 |
Abbreviations: PSA, prostate-specific antigen; VHA, Veterans Health Administration.
Among men aged 40 years or older.
Age adjusted to the 2000 US standard population.